Drug Development

CRITICAL CARE MEDICINE 47m 41s 0.75 Credit CME Coronavirus Update With Peter Piot, MD, PhD JAMA

CRITICAL CARE MEDICINE 38m 26s 0.75 Credit CME Coronavirus Update With Peter Piot, MD, PhD JAMA

INFECTIOUS DISEASES 21m 26s Coronavirus Update With CDC Director Rochelle Walensky JAMA

INFECTIOUS DISEASES 24m 59s 0.5 Credit CME Coronavirus Update With CDC Director Rochelle Walensky, MD JAMA

HEALTH POLICY 1 Credit CME US Food and Drug Administration Support for Oncology Drug Development During COVID-19 JAMA Oncology

CORONAVIRUS (COVID-19) 1 Credit CME The Challenges Ahead With Monoclonal Antibodies: From Authorization to Access JAMA

CORONAVIRUS (COVID-19) 1 Credit CME Therapy for Early COVID-19: A Critical Need JAMA

CORONAVIRUS (COVID-19) 1 Credit CME Study Aims to Identify Drugs That Could Be Repurposed for COVID-19 JAMA

CLINICAL PHARMACY AND PHARMACOLOGY 31m 28s 0.5 Credit CME Ten Things Every New Doctor Should Know About Drug Reactions JAMA

CORONAVIRUS (COVID-19) 1 Credit CME Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies JAMA Internal Medicine

CLINICAL PHARMACY AND PHARMACOLOGY 12m 50s 0.25 Credit CME Update on Dexamethasone for the Treatment of COVID-19 JAMA

DRUG DEVELOPMENT 1 Credit CME Missed Opportunities on Emergency Remdesivir Use JAMA

CLINICAL PHARMACY AND PHARMACOLOGY 36m 28s 0.5 Credit CME Remdesivir and Dexamethasone for the Treatment of COVID-19 JAMA

INFECTIOUS DISEASES 5m 46s Monoclonal Antibodies for Coronavirus JAMA

DRUG DEVELOPMENT 1 Credit CME The Equitable Distribution of COVID-19 Therapeutics and Vaccines JAMA

CORONAVIRUS (COVID-19) 1 Credit CME Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times JAMA

INFECTIOUS DISEASES 37m 56s 0.5 Credit CME The NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Initiative JAMA

INFECTIOUS DISEASES 39m 37s 0.5 Credit CME The NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Initiative JAMA

HEALTH POLICY 1 Credit CME Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity JAMA Network Open

DRUG DEVELOPMENT 1 Credit CME Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies JAMA